New York, USA - 21 Apr `17Celgene: Apremilast with NB-UVB

Official title: A Split Body Study of the Effects of Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo. Phase II

In brief:

  • Procedure: Each participant will be compared with one side of the body to the other side. Enrolled subjects will be randomized to treatment with narrowband UVB two to three times weekly to one half of their body for a total of 16 weeks, while the contralateral side of the body is covered by a special garment to prevent any UVB treatment.
  • Drug: Apremilast (oral tablet) 30 mg orally, twice daily. 

Recruitment status: completed

Start date: April 21, 2017    
Last Update: August 27, 2019

Contact: To learn more about this study, you or your doctor may contact the study research staff. Please refer to this study by its ClinicalTrials.gov identifier NCT03123016

FAQOther Questions

  • Which skin conditions can be mistaken for vitiligo?

    Vitiligo is a common skin condition with characteristic milky white patches of irregular shape. However, several other skin conditions exhibit similar symptoms that can lead to ...

  • Is vitiligo contagious?

    Vitiligo is NOT contagious. It cannot be passed on or caught from touching someone with vitiligo, shaking hands, swimming in the same pool, sharing towels, sitting next to someo...

  • Is there a special diet for vitiligo?

    In short, no.  Some people find that certain foods may worsen their vitiligo symptoms or that others may improve their skin condition. We found no scientific evidence that a sp...